5-(2-chlorobenzyl)-2-methylthio-4-pyrimidone | 63204-42-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5-(2-chlorobenzyl)-2-methylthio-4-pyrimidone
• 英文别名: 2-methylthio-5-(2-chlorobenzyl)pyrimid-4-one；5-(2-chloro-benzyl)-2-methylsulfanyl-3H-pyrimidin-4-one；5-[(2-chlorophenyl)methyl]-2-methylsulfanyl-1H-pyrimidin-6-one
• CAS: 63204-42-2
• 化学式: C₁₂H₁₁ClN₂OS
• 分子量: 266.751
• InChiKey: PHICNKHKQHRGQT-UHFFFAOYSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-chlorobenzyl)-2-methylthio-4-pyrimidone 、 2-(((5-甲基-1H-咪唑-4-基)甲基)硫代)乙胺 生成 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(2-chlorobenzyl)-4-pyrimidone dihydrochloride
  参考文献：
  名称：

  4-Pyrimidone compounds

  摘要：

  这些化合物是取代的异胞嘧啶，是组胺H.sub.2-拮抗剂。本发明的两种特定化合物是2-β2-(5-甲基-4-咪唑基甲硫基)-乙基氨基-5-(3-甲氧基苄基)-4-吡咯啉酮和2-β2-(5-甲基-4-咪唑基甲硫基)乙基氨基-5-苄氧基-4-吡咯啉酮。

  公开号：

  US04145546A1
• 作为产物：
  描述：

  (E)-ethyl 2-chlorocinnamate 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 sodium 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 25.0h， 生成 5-(2-chlorobenzyl)-2-methylthio-4-pyrimidone
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists I. Oxmetidine and related compounds

  摘要：

  DOI：

  10.1016/0223-5234(88)90167-5

文献信息

• 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H.sub.1
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04547506A1

  公开（公告）日：1985-10-15

  Pyridine derivatives are disclosed which are useful as histamine H.sub.1 -antagonists.

  已披露了作为组胺H.sub.1-拮抗剂有用的吡啶衍生物。
• 4-Pyrimidone compounds
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04145546A1

  公开（公告）日：1979-03-20

  The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present invention are 2-\x9b2-(5-methyl-4-imidazolylmethylthio)-ethylamino!-5-(3-methoxybenzyl)-4-p\n' yrimidone and 2-\x9b2-(5-methyl-4-imidazolylmethylthio)ethylamino!-5-benzyloxy-4-pyrimidone\n' .

  这些化合物是取代的异胞嘧啶，是组胺H.sub.2-拮抗剂。本发明的两种特定化合物是2-β2-(5-甲基-4-咪唑基甲硫基)-乙基氨基-5-(3-甲氧基苄基)-4-吡咯啉酮和2-β2-(5-甲基-4-咪唑基甲硫基)乙基氨基-5-苄氧基-4-吡咯啉酮。
• Iso(thio)ureas, processes for their preparation and compositions containing them
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0007232A1

  公开（公告）日：1980-01-23

  Isoureas and isothioureas which are histamine H2- antagonists and also have histamine H1-antagonist activity and antiinflammatory activity having the structure in which R' and R2 are hydrogen, lower alkyl, or together with the carbon and two nitrogen atoms shown form a dihydroimidazolyl or tetrahydropyrimidyl group, Y is sulphur or oxygen, n is from 3 to 8, X is oxygen or sulphur, Z is hydrogen or lower alkyl, A is C1-C3 alkylene or -(CH2)pW(CH2)q- where W is oxygen or sulphur and the sum of p and q is 1 to4, and B is methyl, cycloalkyl, heteroaryl, aryl or, when A is alkylene, hydrogen, are prepared by a process in which a compound of structure where D is HY- or a leaving group is reacted with: (a) when D is HY-, an isothiourea where A is lower alkyl or aryl (lower alkyl), or a cyanamide R1HNCN or a carbodiimide R1N=C=NR2 or (b) when D is a leaving group, a urea or thiourea or, when Y is oxyen a compound of structure where G is a lower alkylthio, chlorine, bromine or NO2NH-, is reacted with an isothiourea of Structure

  异脲类和异硫脲类是组胺 H2-拮抗剂，也具有组胺 H1-拮抗剂活性和抗炎活性，其结构为 其中 R' 和 R2 为氢、低级烷基或与所示的碳原子和两个氮原子一起形成二氢咪唑基或四氢嘧啶基，Y 为硫或氧，n 为 3 至 8，X 为氧或硫，Z 为氢或低级烷基、A 为 C1-C3 亚烷基或-(CH2)pW(CH2)q-，其中 W 为氧或硫，p 和 q 之和为 1 至 4，B 为甲基、环烷基、杂芳基、芳基或（当 A 为亚烷基时）氢，通过以下工艺制备结构如下的化合物 其中 D 为 HY- 或离去基团，并与之反应： (a) 当 D 为 HY- 时，异硫脲 其中 A 为低级烷基或芳基（低级烷基），或氰胺 R1HNCN 或碳化二亚胺 R1N=C=NR2 或 (b) 当 D 为离去基团时，脲或硫脲 或当 Y 为氧烯时，结构如下的化合物 其中 G 为低级烷硫基、氯、溴或 NO2NH- 时，与结构式如下的异硫脲反应
• Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0013071A1

  公开（公告）日：1980-07-09

  The invention provides new histamine H2- antagonist compounds of Structure 1 in which R' is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di(lower alkyl)amino or cyano; R2 is in the 3-, 4- or 5- position and is hydrogen, or R2 is lower alkyl substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy w-substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or-(CH2)pW-(CH2)q-where W is oxygen or sulphur and p and q are such that their sum is from 1 to4, and B is hydrogen, methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is a naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a 4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl(lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di(lower alkyl)amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of Structure 1 can be prepared by reacting a compound of Structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of Structure 2, in which R3 is in the 3-, 4- or 5p position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R' is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed.

  本发明提供了结构 1 的新型组胺 H2- 拮抗剂化合物 其中R'是氢、低级烷基、低级烷氧基、羟基、卤素、三氟甲基、硝基、氨基、低级烷基氨基、低级烷酰氨基、二（低级烷基）氨基或氰基；R2 位于 3-、4-或 5-位且为氢，或 R2 为被氨基、低级烷基氨基、二（低级烷基）氨基、N-哌啶基或 N-吡咯烷基取代的低级烷基，或 R2 为被氨基、低级烷基氨基、二（低级烷基）氨基、N-哌啶基或 N-吡咯烷基取代的乙氧基或丙氧基；Y 为亚甲基或氧，X 为亚甲基或硫，条件是 X 和 Y 中的一个或两个基团为亚甲基；Z 为氢或低级烷基；A是C1-C5亚烷基或-(CH2)pW-(CH2)q-其中W是氧或硫，p和q的和为1至4，B是氢、甲基、C3-C6环烷基、任选被一个或多个基团低级烷基、低级烷氧基、卤代、羟基和氨基取代的杂芳基，或者B是萘基、6-(2,3-二氢-1,4-苯并二噁烷基)、4-或5-(1、3-苯并二恶茂基）基团，或任选被一个或多个低级烷基、低级烷氧基、卤素、芳基（低级烷氧基）、羟基、低级烷氧基-低级烷氧基、三氟甲基、二（低级烷基）氨基、苯氧基、卤代苯氧基、低级烷氧基苯氧基、苯基、卤代苯基或低级烷氧基苯基基团取代的苯基基团以及含有它们的药物组合物。结构 1 的化合物可通过结构 3 的化合物（其中 Q 为硝基氨基、低级烷硫基、苄硫基或卤素） 与结构 2 的胺反应制备，其中 R3 位于 3-、4-或 5p 位，是氢、被基团 R4 取代的低级烷基或 R4CH2CH2O- 或 R4CH2CH2CH2O-，其中 R' 是二（低级烷基）氨基、N-哌啶基、N-吡咯烷基、受保护的氨基或受保护的低级烷基氨基，必要时去除取代基 R3 中存在的任何氨基保护基。
• Pyridine derivatives
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0113572A2

  公开（公告）日：1984-07-18

  The present invention provides compounds of formula (1): and pharmaceutically acceptable salts thereof where R1 and R2 are the same or different and are hydrogen, C1-6 alkyl, C1-6 alkoxy, or halogen; R3 is C,.e alkyl, C3.8 cycloalkyl C1-6 alkyl, optionally substituted phenyl or optionally substituted phenyl C1-6 alkyl, where the optional substituents are one or more C1-6 alkyl, C1-6 alkoxy, halogen, or hydroxy groups; or is optionally substituted pyridyl or optionally substituted pyridyl C1-6 alkyl where the optional substituents are one or more C1-6 alkyl or C1-6 alkoxy groups or halogen atoms; a is from 2 to 4 b is from 1 to 6 R4 is hydrogen, optionally substituted phenyl where the optional substituents are one or more C1-6 alkyl, C1-6 alkoxy, nitro or hydroxy groups or halogen atoms, or a methylenedioxy group, or is an optionally substituted pyridyl group where the optional substituents are one or more C1-6 alkyl, C1-6 alkoxy groups or halogen atoms; or is a C3-8 cycloalkyl group; or is N-oxo-3-pyridyl; N-oxo-6-methyl-3-pyridyl; 6-hydroxymethyl-3-pyridyl; N-oxo-4,6-dimethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; N-oxo-5,6-dimethyl-3-pyridyl; 6-hydroxymethyl-5-methyl-3-pyridyl; or N-oxo-4-pyridyl, or is a pyridone group in which the nitrogen atom is optionally substituted with C1-6 alkyl. The compounds of this invention are useful as histamine H,-antagonists.

  本发明提供了式(1)化合物： 及其药学上可接受的盐类，其中 R1 和 R2 相同或不同，并且是氢、C1-6 烷基、C1-6 烷氧基或卤素； R3 是 C,.e烷基、C3.8 环烷基 C1-6烷基、任选取代的苯基或任选取代的苯基 C1-6烷基，其中任选取代基是一个或多个 C1-6烷基、C1-6烷氧基、卤素或羟基；或者是任选取代的吡啶基或任选取代的吡啶基 C1-6烷基，其中任选取代基是一个或多个 C1-6烷基或 C1-6烷氧基或卤素原子； a 是 2 至 4 b 是 1 至 6 R4是氢、任选取代的苯基（其中任选取代基是一个或多个C1-6烷基、C1-6烷氧基、硝基或羟基或卤素原子）或亚甲基二氧基、 或任选取代基为一个或多个 C1-6 烷基、C1-6 烷氧基或卤素原子的吡啶基； 或 C3-8 环烷基；或 N-氧代-3-吡啶基；N-氧代-6-甲基-3-吡啶基； 6-羟甲基-3-吡啶基；N-氧代-4,6-二甲基-3-吡啶基；6-羟甲基-4-甲基-3-吡啶基；N-氧代-5,6-二甲基-3-吡啶基；6-羟甲基-5-甲基-3-吡啶基；或 N-氧代-4-吡啶基，或氮原子被 C1-6 烷基任选取代的吡啶酮基团。本发明的化合物可用作组胺 H拮抗剂。